Patents by Inventor Jeffrey Claude Pelletier
Jeffrey Claude Pelletier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12172974Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: September 8, 2022Date of Patent: December 24, 2024Assignees: Biohaven Pharmaceutical Holding Company Ltd., Rutgers, The State University of New JerseyInventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
-
Patent number: 12030868Abstract: Disclosed are prodrugs of CGRP antagonists, methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof the prodrugs, pharmaceutical compositions comprising prodrugs and kits including the pharmaceutical compositions and instructions for use.Type: GrantFiled: October 10, 2019Date of Patent: July 9, 2024Assignee: Pfizer Ireland PharmaceuticalsInventors: Charles M. Conway, Gene M. Dubowchik, Jeffrey Claude Pelletier, Allen B. Reitz
-
Patent number: 12005046Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: February 1, 2021Date of Patent: June 11, 2024Assignee: Biohaven Therapeutics Ltd.Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20240018121Abstract: Pharmaceutical compositions include heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.Type: ApplicationFiled: June 3, 2021Publication date: January 18, 2024Applicant: FOX CHASE CHEMCIAL DIVERSITY CENTER, INC.Inventors: Simon David Peter BAUGH, Kathryn B. FREEMAN, Jeffrey Claude PELLETIER, Allen B. REITZ, Richard W. SCOTT, Garry Robert SMITH, Sandeep THANNA, Damian G. WEAVER, David B. WHITMAN
-
Publication number: 20230202993Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: September 8, 2022Publication date: June 29, 2023Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
-
Patent number: 11566016Abstract: The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38? MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.Type: GrantFiled: September 16, 2021Date of Patent: January 31, 2023Assignees: The Trustees of Columbia University in the City of New York, Northwestern UniversityInventors: Ottavio Arancio, Daniel Martin Watterson, Jeffrey Claude Pelletier, Saktimayee Mitra Roy
-
Patent number: 11440893Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: November 23, 2020Date of Patent: September 13, 2022Assignees: Biohaven Pharmaceutical Holding Company Ltd., Rutgers, The State University of New JerseyInventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
-
Publication number: 20220009905Abstract: The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38? MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.Type: ApplicationFiled: September 16, 2021Publication date: January 13, 2022Inventors: Ottavio ARANCIO, Daniel Martin WATTERSON, Jeffrey Claude PELLETIER, Saktimayee Mitra ROY
-
Publication number: 20210395223Abstract: Disclosed are prodrugs of CGRP antagonists, methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof the prodrugs, pharmaceutical compositions comprising prodrugs and kits including the pharmaceutical compositions and instructions for use.Type: ApplicationFiled: October 10, 2019Publication date: December 23, 2021Inventors: Charles M. Conway, Gene M. Dubowchik, Jeffrey Claude Pelletier, Allen B. Reitz
-
Patent number: 11149020Abstract: The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38? MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.Type: GrantFiled: August 27, 2019Date of Patent: October 19, 2021Assignees: The Trustees of Columbia University in the City of New York, Northwestern UniversityInventors: Ottavio Arancio, Daniel Martin Watterson, Jeffrey Claude Pelletier, Saktimayee Mitra Roy
-
Publication number: 20210236471Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: February 1, 2021Publication date: August 5, 2021Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20210236470Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: January 18, 2021Publication date: August 5, 2021Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20210228549Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: January 18, 2021Publication date: July 29, 2021Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20210078962Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: November 23, 2020Publication date: March 18, 2021Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
-
Patent number: 10844026Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: January 21, 2020Date of Patent: November 24, 2020Assignees: Biohaven Pharmaceutical Holding Company Ltd., Rutgers, The State University of New JerseyInventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
-
Publication number: 20190389840Abstract: The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38? MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.Type: ApplicationFiled: August 27, 2019Publication date: December 26, 2019Inventors: Ottavio ARANCIO, Daniel Martin WATTERSON, Jeffrey Claude PELLETIER, Saktimayee Mitra ROY
-
Patent number: 10428047Abstract: The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38? MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.Type: GrantFiled: September 7, 2017Date of Patent: October 1, 2019Assignees: The Trustees of Columbia University in the City of New York, Northwestern UniversityInventors: Ottavio Arancio, Daniel Martin Watterson, Jeffrey Claude Pelletier, Saktimayee Mitra Roy
-
Publication number: 20180036290Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: February 26, 2016Publication date: February 8, 2018Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Gary Robert Smith, Haiyan Bian
-
Publication number: 20180037557Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: February 26, 2016Publication date: February 8, 2018Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Gary Robert Smith, Haiyan Bian
-
Publication number: 20170369472Abstract: The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38? MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.Type: ApplicationFiled: September 7, 2017Publication date: December 28, 2017Inventors: Ottavio ARANCIO, Daniel Martin WATTERSON, Jeffrey Claude PELLETIER, Saktimayee Mitra ROY
